Patients with rosacea who experience burning reported that winter months, significant temperature chances, and dietary habits trigger burning.

The EFFISAYIL ON study demonstrated that IV spesolimab may be an effective rescue therapy for GPP patients on SC spesolimab who experience a GPP flare.

The Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for obinutuzumab for the treatment of systemic lupus erythematosus (SLE). Findings ...

Drug prices have increased overall during President Donald Trump's negotiations on "most favored nation" drug pricing.

Funding disruptions by the Trump administration preceded decreases in HIV testing, diagnosis, prevention, and treatment among infants.

The US Environmental Protection Agency has delayed making decisions on allowed uses for forever chemicals or PFAS.

Patients with ophiasis may be categorized into 3 distinct subtypes that can guide early intervention and stratify treatment.

Blaine Labs recalls Revitaderm and Tridergel wound care gels due to microbial contamination with Lysinibacillus fusiformis.

Promising early results regarding the use of litifilimab in patients with CLE were presented as part of a late-breaking session at the 2026 AAD Annual Meeting.

Real-world data on spesolimab have shown rapid improvement in acute flares of GPP, along with a favorable safety profile, according to a systemic review.

After months of leadership changes, President Donald Trump has chosen a new candidate to lead the U.S. Centers for Disease Control and Prevention (CDC). The White House announced Thursday that Dr.

Superior efficacy and comparable safety was seen with DFD-29 in patients with rosacea when compared with the current first-line systemic.